🟢 AIM ImmunoTech is trading 5.7% up today with broader biotechnology momentum

AIM ImmunoTech is trading 5.7% up at $0.27, with broader biotechnology momentum and improving risk appetite appearing to support the move.

• The stock extended recent gains after closing at $0.25 on August 20.
• No new company-specific announcement was identified on August 21; the latest substantial update was the August 10 second-quarter report.
• AIM recently reported progress toward planned Phase 3 pancreatic-cancer development and DURIPANC execution.